Foresite Capital Fund IV, L.P. - 30 Sep 2025 SCHEDULE 13G/A Report for Maze Therapeutics, Inc. Common Stock, par value $0.001 (MAZE)

Filing Manager
Foresite Capital Fund IV, L.P.
Reporting Manager
James Tananbaum
Security
Maze Therapeutics, Inc. Common Stock, par value $0.001
Symbol
MAZE
Shares outstanding
43,496,286 shares
Disclosed Ownership
608,948 shares
Ownership
1.4%
Form type
SCHEDULE 13G/A
Filing time
14 Nov 2025, 16:04:27 UTC
Date of event
30 Sep 2025
Previous filing
07 Feb 2025
SEC
View on sec.gov

Quoteable Key Fact

"Foresite Capital Fund IV, L.P. disclosed 1.4% ownership in Maze Therapeutics, Inc. Common Stock, par value $0.001 (MAZE) on 30 Sep 2025."

Quick Takeaways

  • Foresite Capital Fund IV, L.P. filed SCHEDULE 13G/A for Maze Therapeutics, Inc. Common Stock, par value $0.001 (MAZE).
  • Disclosed ownership: 1.4%.
  • Date of event: 30 Sep 2025.

What Changed

  • Previous schedule filing date: 07 Feb 2025.
  • Current filing was accepted on 14 Nov 2025, 16:04.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (5)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Foresite Capital Fund IV, L.P. 1.2% 522,657 522,657 0 /s/ James Tananbaum James Tananbaum, Managing Member of the General Partner
Foresite Capital Management IV, LLC 1.2% 522,657 522,657 0 /s/ James Tananbaum James Tananbaum, Managing Member
Foresite Capital Fund V, L.P. 0.2% 86,291 86,291 0 /s/ James Tananbaum James Tananbaum, Managing Member of the General Partner
Foresite Capital Management V, LLC 0.2% 86,291 86,291 0 /s/ James Tananbaum James Tananbaum, Managing Member
James Tananbaum 1.4% 608,948 608,948 0 /s/ James Tananbaum James Tananbaum